FIELD: chemistry.
SUBSTANCE: in formula III:
,
each of X1 and X2 is independently selected from a bond, -CH2-, -O- or -S- and at least one of X1 and X2 is selected from -CH2-, -O- or -S-; each of R7 and R8 is independently selected from hydrogen or C6aryl, optionally substituted with one or more Ra and at least one of R7 and R8 is selected from C6aryl, optionally substituted with one or more Ra; each of Z1 and Z2 is selected from -N(RB)-, each of W1, W2, W3, W4, W5, W6, W7 and W8 is independently selected from N or C(Rd), where Rd in each case is selected from hydrogen; each of R1, R2, R9, R11, R12, R14, R15 and R16 in each case is independently selected from hydrogen or Ra; each of m and n is 0; Ra in each case is independently selected from halogen, hydroxy group, amino group, -LA and -Ls-Re; La in each case is selected from C1-C6-alkyl; values of radicals T, Rb, Rb', Re are given in the claim. The invention also relates to a pharmaceutical composition containing said compounds, a method of inhibiting HCV replication, a method of treating HCV infection and a method of producing said compounds.
EFFECT: high efficiency of using compounds.
7 cl, 6 tbl, 28 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIVIRAL COMPOUNDS | 2009 |
|
RU2505540C2 |
ANTIVIRAL COMPOUNDS | 2010 |
|
RU2541571C2 |
ANTIRETROVIRAL COMPOUNDS AND USE THEREOF | 2010 |
|
RU2571662C2 |
ANTIVIRAL COMPOUND | 2006 |
|
RU2441010C2 |
ANTIVIRAL COMPOUNDS AND THEIR APPLICATION | 2010 |
|
RU2552533C2 |
BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773346C2 |
ISOXAZOLINE AS FATTY ACID AMIDE HYDROLASE INHIBITORS | 2010 |
|
RU2539595C2 |
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE FOR TREATMENT OF PATHOLOGICAL CONDITIONS | 2017 |
|
RU2773333C2 |
MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
NEUROACTIVE STEROIDS, COMPOSITIONS AND THEIR USE | 2014 |
|
RU2754534C2 |
Authors
Dates
2014-01-27—Published
2009-12-22—Filed